Carbon Cloud Peptech Secures Strategic Investment from Hyndor Pharma, Elevating Collaboration to a New Level

On July 1, 2025, iCarbonX All received strategic investment from Hybio Pharmaceutical. Both parties simultaneously signed the "Strategic Cooperation Agreement for Innovative Drug CRDMO Services." This move not only deepens and upgrades the cooperation between the two enterprises in the peptide innovative drug field but also highlights the core strength and industry recognition of iCarbonX All’s “Peptide Chip + Artificial Intelligence” innovative drug screening platform, injecting new momentum into the globalization journey of China's original peptide drugs.

Since its establishment, iCarbonX All has always regarded technological innovation as its core driving force. Its self-developed silicon-based polypeptide chip technology breaks through traditional limitations. Combined with an artificial intelligence-powered high-throughput screening platform, it has become a unique and leading tool globally for the large-scale and efficient detection of protein interactions. This platform can precisely screen the "optimal" drug candidate molecules from massive data, rapidly completing the drug discovery phase, and acting as an "accelerator" for innovative drug research and development. Currently, the iCPDC-001 oncology project and the AI antimicrobial peptide project, both advanced through this platform, demonstrate Best-In-Class potential, with their pipeline strength continuing to lead the industry.

As a leading enterprise in the peptide industry, Hybio Pharmaceutical has profound expertise in industrialization, globalization, and CRDMO services. Since establishing a strategic cooperation framework in 2024, the synergy between the two parties has continued to stand out. Significant progress has been made in the jointly developed GLP-1R/GIPR/GCGR triple agonist project as of May 2025. Based on the close collaboration and excellent synergy in innovative drug projects such as the GLP-1R/GIPR/GCGR triple agonist, and to further deepen the cooperative relationship, Hybio Pharmaceutical and iCarbonX All have signed the "Strategic Investment Agreement." This will allow Hybio Pharmaceutical to deeply participate in the future development and growth of iCarbonX All through strategic investment. This dual binding of capital and business not only represents high recognition of iCarbonX All’s technology platform and pipeline potential but also marks an upgraded practice of the concept of "complementary advantages and resource sharing."

According to the agreement, Hybio Pharmaceutical will fully leverage its advantages in the CRDMO field to comprehensively support the development of multiple innovative drug projects under iCarbonX All, including PDC peptide-drug conjugates and AI antimicrobial peptides. The collaboration will cover all key stages from preclinical research to commercial production. This partnership will accelerate the translation of innovative achievements from the laboratory to clinical applications, enabling advanced technologies to be transformed into medicines that benefit patients more rapidly.

As an innovative drug research and development enterprise dedicated to promoting China-originated peptide drugs globally, we hope more industry partners will utilize the iCarbonX All technology platform, join the iCarbonX All R&D ecosystem, accelerate pipeline implementation through business cooperation, deepen innovation synergy through capital ties, achieve true deep integration, and jointly promote the availability of China-originated peptide drugs for patients worldwide!

This strategic investment is a strong testament to the technical value of iCarbonX All and reflects the industry's firm confidence in the future of innovative drug screening platforms. In the future, iCarbonX All will continue to drive development through technological innovation and foster growth via open collaboration. By partnering with more strategically-minded collaborators, it aims to achieve mutual success on the global stage of peptide-based innovative drugs, showcasing China’s homegrown research and development strength to the world.